Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryutaro Asano

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
Cancer Letters|July 13, 2007
High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphomaNorihiko Akamatsu, Yasuaki Yamada, Hiroo Hasegawa, et al.
Nanomaterials (Basel, Switzerland)|September 13, 2024
Potential of Enzymatically Synthesized Hemozoin Analog as Th1 Cell AdjuvantKazuaki Hoshi, Anh Thi Tram Tu, Miwako Shobo, et al.
Immunology Letters|February 20, 2002
Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodiesHideaki Kodama, Masanori Suzuki, Yu Katayose, et al.
Cancer Immunology, Immunotherapy : CII|February 15, 2002
A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinomaShin-ichi Takemura, Toshio Kudo, Ryutaro Asano, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|September 24, 2024
Proximity-Unlocked Luminescence by Sequential Enzymatic Reactions from Antibody and Antibody/Aptamer (PULSERAA): A Platform for Detection and Visualization of Virus-Containing SpotsDaimei Miura, Wakana Hayashi, Kensuke Hirano, et al.
Cancer Immunology, Immunotherapy : CII|December 3, 2003
A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cellsHiroki Hayashi, Ryutaro Asano, Kouhei Tsumoto, et al.
Cell Reports|July 15, 2025
Bispecific antibody-antigen complex structures reveal activity enhancement by domain rearrangementKyohei Sato, Shiro Uehara, Atsushi Tsugita, et al.
Protein Engineering, Design & Selection : PEDS|March 8, 2013
Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabodyRyutaro Asano, Takashi Kumagai, Keisuke Nagai, et al.
Biosensors & Bioelectronics|February 3, 2022
Development of a DNA aptamer that binds to the complementarity-determining region of therapeutic monoclonal antibody and affinity improvement induced by pH-change for sensitive detectionTaro Saito, Yutaka Shimizu, Kaori Tsukakoshi, et al.
Oncology Reports|July 12, 2011
In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibodyYasuhiro Watanabe, Ryutaro Asano, Kyoko Arai, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Cancer Letters|July 13, 2007
High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphomaNorihiko Akamatsu, Yasuaki Yamada, Hiroo Hasegawa, et al.
Nanomaterials (Basel, Switzerland)|September 13, 2024
Potential of Enzymatically Synthesized Hemozoin Analog as Th1 Cell AdjuvantKazuaki Hoshi, Anh Thi Tram Tu, Miwako Shobo, et al.
Immunology Letters|February 20, 2002
Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodiesHideaki Kodama, Masanori Suzuki, Yu Katayose, et al.
Cancer Immunology, Immunotherapy : CII|February 15, 2002
A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinomaShin-ichi Takemura, Toshio Kudo, Ryutaro Asano, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|September 24, 2024
Proximity-Unlocked Luminescence by Sequential Enzymatic Reactions from Antibody and Antibody/Aptamer (PULSERAA): A Platform for Detection and Visualization of Virus-Containing SpotsDaimei Miura, Wakana Hayashi, Kensuke Hirano, et al.
Cancer Immunology, Immunotherapy : CII|December 3, 2003
A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cellsHiroki Hayashi, Ryutaro Asano, Kouhei Tsumoto, et al.
Cell Reports|July 15, 2025
Bispecific antibody-antigen complex structures reveal activity enhancement by domain rearrangementKyohei Sato, Shiro Uehara, Atsushi Tsugita, et al.
Protein Engineering, Design & Selection : PEDS|March 8, 2013
Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabodyRyutaro Asano, Takashi Kumagai, Keisuke Nagai, et al.
Biosensors & Bioelectronics|February 3, 2022
Development of a DNA aptamer that binds to the complementarity-determining region of therapeutic monoclonal antibody and affinity improvement induced by pH-change for sensitive detectionTaro Saito, Yutaka Shimizu, Kaori Tsukakoshi, et al.
Oncology Reports|July 12, 2011
In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibodyYasuhiro Watanabe, Ryutaro Asano, Kyoko Arai, et al.
Pageof 12